We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial.
- Authors
Jiang, Qian; Li, Zongru; Qin, Yazhen; Li, Weiming; Xu, Na; Liu, Bingcheng; Zhang, Yanli; Meng, Li; Zhu, Huanling; Du, Xin; Chen, Suning; Liang, Yang; Hu, Yu; Liu, Xiaoli; Song, Yongping; Men, Lichuang; Chen, Zi; Niu, Qian; Wang, Hengbang; Lu, Ming
- Abstract
Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial. Correction to: Journal of Hematology & Oncology (2022) 15:113 https://doi.org/10.1186/s13... The original article [[1]] contained three erroneous citations and other minor typesetting errors in the text which have since been amended.
- Subjects
CHRONIC myeloid leukemia; PROTEIN-tyrosine kinase inhibitors; NILOTINIB
- Publication
Journal of Hematology & Oncology, 2022, Vol 15, Issue 1, p1
- ISSN
1756-8722
- Publication type
Correction Notice
- DOI
10.1186/s13045-022-01334-z